Trial Profile

Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Selinexor (Primary) ; Antineoplastics
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms LAUNCH

Most Recent Events

11 Nov 2022 New trial record
06 Nov 2022 According to an Antengene Corporation media release, data from this study will be presented at the upcoming 2022 American Society of Hematology (ASH) Annual Meeting.
06 Nov 2022 Results presented in an Antengene Corporation media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com